Inzamoda (Enzalutamide)

Enzalutamide is an androgen‑receptor antagonist. It binds to the receptor with high affinity, blocks androgen binding, prevents the receptor from moving into the cell nucleus, and stops DNA binding and co‑activator recruitment. This disrupts androgen‑driven gene transcription that fuels prostate‑cancer cell proliferation.

The dosing regimen for Inzamoda is determined by the prescribing clinician based on the patient’s clinical status, renal and hepatic function, and concomitant medications. Physicians follow approved labeling and adjust the dose as needed; patients should follow the exact instructions provided by their healthcare professional.

Enzalutamide is classified as pregnancy category unknown and is not recommended for use during pregnancy or lactation. Because it may affect fetal development and can be excreted in breast milk, women of child‑bearing potential should use effective contraception and discuss risks with their physician.

To request Inzamoda, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inzamoda (enzalutamide) is a second‑generation nonsteroidal antiandrogen with higher affinity for the androgen receptor than older agents such as bicalutamide. Compared with alternatives like apalutamide or darolutamide, enzalutamide has a well‑established efficacy profile but may carry a higher risk of seizures, requiring individual risk assessment.

Store Inzamoda tablets at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use. Do not store in a refrigerator or freezer.

Inzamoda is taken orally as a tablet. It can be swallowed whole with water, with or without food, as directed by the prescriber. Patients should not crush, split, or chew the tablet unless specifically instructed, to maintain consistent drug absorption.

The most serious adverse events associated with Inzamoda include seizures, severe hypertension, and hepatic injury. Patients should be educated to report any new seizure activity, sudden increases in blood pressure, jaundice, or unexplained abdominal pain promptly so that appropriate medical evaluation can be performed.

Inzamoda is contraindicated in patients with a known history of seizures, uncontrolled hypertension, or severe hepatic impairment. It should also be avoided in individuals taking strong CYP2C8 inhibitors or in those with hypersensitivity to enzalutamide or any tablet excipients.